Berkeley Inc Decreases Stake in Medpace Holdings, Inc. $MEDP

Berkeley Inc trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 44.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,667 shares of the company’s stock after selling 2,172 shares during the period. Berkeley Inc’s holdings in Medpace were worth $1,371,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Wasatch Advisors LP raised its stake in Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Mawer Investment Management Ltd. raised its position in shares of Medpace by 17.4% during the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after buying an additional 121,213 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Medpace by 15.1% in the 2nd quarter. AQR Capital Management LLC now owns 621,184 shares of the company’s stock valued at $193,269,000 after acquiring an additional 81,637 shares during the last quarter. TD Asset Management Inc grew its position in Medpace by 15.6% in the second quarter. TD Asset Management Inc now owns 457,645 shares of the company’s stock worth $143,636,000 after acquiring an additional 61,764 shares in the last quarter. Finally, Epoch Investment Partners Inc. grew its position in Medpace by 11.4% in the second quarter. Epoch Investment Partners Inc. now owns 445,231 shares of the company’s stock worth $139,740,000 after acquiring an additional 45,435 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Medpace Stock Performance

NASDAQ:MEDP opened at $602.40 on Wednesday. The firm has a 50-day simple moving average of $582.94 and a 200-day simple moving average of $516.67. Medpace Holdings, Inc. has a one year low of $250.05 and a one year high of $628.92. The firm has a market cap of $16.97 billion, a P/E ratio of 42.13, a P/E/G ratio of 2.05 and a beta of 1.43.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm had revenue of $659.90 million during the quarter, compared to analysts’ expectations of $640.49 million. During the same period in the prior year, the business posted $3.01 EPS. The firm’s quarterly revenue was up 23.7% on a year-over-year basis. On average, research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on MEDP shares. Zacks Research lowered Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Cowen restated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Mizuho set a $660.00 price objective on shares of Medpace in a research report on Friday, January 9th. Barclays increased their target price on shares of Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Finally, Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a research note on Saturday. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, Medpace currently has a consensus rating of “Reduce” and an average target price of $491.27.

Insiders Place Their Bets

In other Medpace news, President Jesse J. Geiger sold 21,503 shares of the stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $595.66, for a total transaction of $12,808,476.98. Following the completion of the sale, the president directly owned 15,000 shares of the company’s stock, valued at approximately $8,934,900. This represents a 58.91% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the transaction, the vice president directly owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 387,925 shares of company stock worth $233,386,647. 20.30% of the stock is owned by corporate insiders.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.